Loading...
•
Sep 30, 2024
Novavax Q3 2024 Earnings Report
Announced financial results and operational highlights for the third quarter ended September 30, 2024.
Key Takeaways
Novavax reported total revenue of $85 million for Q3 2024, with product sales contributing $38 million and licensing, royalties, and other revenue at $46 million. The company ended the quarter with $1 billion in cash and receivables and is advancing its R&D strategy beyond COVID-19 and influenza.
Achieved total revenue of $85 million in the third quarter of 2024.
Ended the third quarter of 2024 with $1 billion in cash and receivables.
Received authorization from U.S. FDA and European Commission for updated 2024-2025 formula COVID-19 vaccine in individuals aged 12 and older.
U.S. FDA removes clinical hold on Investigational New Drug application for COVID-19-Influenza Combination and stand-alone influenza vaccine candidates.
Novavax
Novavax
Novavax Revenue by Segment
Revenue by Segment
Product sales Revenue
CapyFin.comLicensing, royalties, and other Revenue
CapyFin.com Forward Guidance
Novavax is updating its Full Year 2024 Financial Guidance and expects to achieve the following objectives.
Positive Outlook
- Full year 2024 Licensing, royalties and other revenue guidance includes $450 million of revenue recognition from the $500 million Sanofi agreement upfront payment
- Full year 2024 Licensing, royalties and other revenue guidance includes $25 million in royalty and other revenue from partner-related activities.
- The company is targeting full year combined R&D and SG&A expenses of approximately $500 million for full year 2025.
- The company is targeting full year combined R&D and SG&A expenses of approximately $350 million for full year 2026.
- Achievement of BLA approval triggers a $175 million milestone payment from Sanofi.
Challenges Ahead
- Full year 2024 product sales guidance reflects approximately $100 million in APA dose deliveries in 1H 2024.
- Full year 2024 product sales guidance reflects $75 million to $125 million of commercial market sales in 2H 2024.
- Challenges related to Novavax’s partnership with Sanofi and in pursuing additional partnership opportunities.
- Challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification, assay validation and stability testing, necessary to satisfy applicable regulatory authorities.
- Manufacturing, distribution or export delays or challenges.
Revenue & Expenses
Visualization of income flow from segment revenue to net income